Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy.

The treatment of prostate cancer with low dose rate prostate brachytherapy has grown rapidly in the last 20 years. Outcome analyses performed in this period have enriched understanding of this modality. This article focuses on the development of a real-time ultrasound-guided implant technique, the importance of radiation dose, trimodality treatment of high-risk disease, long-term treatment outcomes, and treatment-associated morbidity.

[1]  R. Stock,et al.  Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? , 2010, The Journal of urology.

[2]  R. Stock,et al.  The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.

[3]  G. Grabenbauer,et al.  Early results of pulsed-dose-rate interstitial brachytherapy for head and neck malignancies after limited surgery. , 2000, International journal of radiation oncology, biology, physics.

[4]  H. Matzkin,et al.  Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning. , 2003, Urology.

[5]  R. Stock,et al.  (125)I monotherapy using D90 implant doses of 180 Gy or greater. , 2008, International journal of radiation oncology, biology, physics.

[6]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[7]  Andrew K. Lee.  Radiation therapy combined with hormone therapy for prostate cancer. , 2006, Seminars in radiation oncology.

[8]  R. Stock,et al.  Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? , 2008, Brachytherapy.

[9]  M. Kattan,et al.  Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[10]  F. Critz,et al.  Prostate specific antigen‐monitored combination radiotherapy for patients with prostate cancer. I‐125 implant followed by external‐beam radiation , 1995, Cancer.

[11]  H. Holm,et al.  Transperineal I-125 seed implantation in prostate cancer guided by transrectal ultrasound. , 1987, Progress in clinical and biological research.

[12]  K. Wallner,et al.  Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. , 2007, International journal of radiation oncology, biology, physics.

[13]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[14]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[15]  Howard Pai,et al.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.

[16]  W. J. Morris,et al.  Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[17]  Stone Nn,et al.  Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. , 2000 .

[18]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[19]  J. Blasko,et al.  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[20]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Mabjeesh,et al.  Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. , 2007, Urology.

[22]  H. Holm,et al.  Ultrasonically guided precise needle placement in the prostate and the seminal vesicles. , 1981, The Journal of urology.

[23]  P. Unger,et al.  Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. , 2008, Brachytherapy.

[24]  J J Prete,et al.  Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[25]  Louis Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[26]  Wayne M Butler,et al.  Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[27]  R. Stock,et al.  Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. , 2005, The Journal of urology.

[28]  P. Scardino,et al.  Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. , 2006, The Journal of urology.

[29]  R. Stock,et al.  Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. , 1998, Radiation oncology investigations.

[30]  W. Catalona,et al.  Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. , 2007, Urology.

[31]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[32]  K. Wallner,et al.  Erectile function durability following permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[33]  R. Stock,et al.  Disease-specific survival following the brachytherapy management of prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[34]  Mark J Rivard,et al.  American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. , 2007, Brachytherapy.

[35]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.

[37]  P G Koutrouvelis,et al.  Prostatourethral‐rectal fistula after prostate brachytherapy , 2000, Cancer.

[38]  K. Wallner,et al.  Long‐term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‐risk features , 2007, Cancer.

[39]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[40]  Nelson N. Stone,et al.  Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. , 2000, International journal of radiation oncology, biology, physics.

[41]  P. Unger,et al.  Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. , 2008, International journal of radiation oncology, biology, physics.

[42]  K. Wallner,et al.  Clinical course of rectal bleeding following I-125 prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[43]  L. Potters,et al.  Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[44]  E. Messing,et al.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Kattan,et al.  Importance of implant dosimetry for patients undergoing prostate brachytherapy. , 2003, Urology.

[46]  S. Nag.  Principles and practice of brachytherapy , 1997 .

[47]  Utilization and outcomes of minimally invasive radical prostatectomy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  L. Salomon,et al.  The outcome of patients with pathological Gleason score ≥8 prostate cancer after radical prostatectomy , 2008, BJU international.

[49]  K. Wallner,et al.  The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. , 2007, Brachytherapy.

[50]  J. W. Stallings,et al.  Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. , 1999, International journal of radiation oncology, biology, physics.

[51]  W. Lee,et al.  A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[52]  K. Wallner,et al.  The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. , 2006, International journal of radiation oncology, biology, physics.

[53]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[54]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[55]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[56]  P. Clark,et al.  Dosimetric Quantifiers for Low Dose Rate Prostate Brachytherapy: V100 Is Superior to D90 , 2005 .

[57]  Robert W Galbreath,et al.  15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. , 2007, International journal of radiation oncology, biology, physics.

[58]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[59]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[60]  R. Stock,et al.  Prostate brachytherapy: treatment strategies. , 1999, The Journal of urology.

[61]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[62]  J. Blasko,et al.  Brachytherapy for prostate cancer , 1995, CA: a cancer journal for clinicians.

[63]  D. Kuban,et al.  Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. , 2009, Urology.

[64]  S Nag,et al.  Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.

[65]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[66]  L. Potters,et al.  A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[67]  M. Sarosdy.  Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy , 2004, Cancer.

[68]  L L Anderson,et al.  Spacing nomograph for interstitial implants of 125I seeds. , 1976, Medical physics.

[69]  J. Ciezki,et al.  Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. , 2003, Urology.

[70]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[71]  F. Critz,et al.  10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. , 2004, The Journal of urology.

[72]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[73]  R. Stock,et al.  Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. , 2006, International journal of radiation oncology, biology, physics.

[74]  K. Wallner,et al.  Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. , 1997, International journal of radiation oncology, biology, physics.

[75]  R. Stock,et al.  Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. , 2001, The Journal of urology.

[76]  R. Stock,et al.  Importance of post-implant dosimetry in permanent prostate brachytherapy. , 2002, European urology.

[77]  J. Ciezki.  Brachytherapy for localized prostate cancer. , 2009, Urology.

[78]  J. Cohen,et al.  Complications after prostate brachytherapy in the Medicare population. , 2000, Urology.

[79]  E. Bergstralh,et al.  Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. , 2002, The Journal of urology.

[80]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[81]  H. Ragde,et al.  Brachytherapy for clinically localized prostate cancer. , 2000, Seminars in surgical oncology.

[82]  R. Stock,et al.  Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. , 2003, Brachytherapy.

[83]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[84]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[85]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[86]  J M Collins,et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. , 1998, International journal of radiation oncology, biology, physics.

[87]  A. D'Amico,et al.  Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Payne,et al.  Original Articles: Prostate Cancer , 1995 .

[89]  R. Clough,et al.  Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. , 2008, Brachytherapy.

[90]  G. Lederman,et al.  High dose combination radiotherapy for the treatment of localized prostate cancer. , 1998, The Journal of urology.

[91]  N. Konishi,et al.  Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. , 2009, Urology.

[92]  R. Stock,et al.  Outcomes for patients with high‐grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy , 2009, BJU international.

[93]  T. D. de Reijke,et al.  Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. , 1993, British journal of urology.